FyoniBio, Alder Therapeutics, and BioLamina enter Consortium Grant Agreement to Propel Recombinant Human Laminin Development for Clinical Applications
FyoniBio, a specialist in tailored cell line and process development, has partnered with BioLamina and Alder Therapeutics in a grant-funded consortium aimed at enabling the production of full-length human recombinant laminins for clinical use. Together, the three companies combine deep scientific expertise in complex protein production, laminin-based cell culture, and stem cell therapy development. The collaboration will support the development of new manufacturing processes and help expand the therapeutic potential of allogeneic cell therapies.
